<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4090">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390126</url>
  </required_header>
  <id_info>
    <org_study_id>BOULIN AOIc 2020</org_study_id>
    <nct_id>NCT04390126</nct_id>
  </id_info>
  <brief_title>COVID-19 Related Lockdown Effects On Chronic Diseases</brief_title>
  <acronym>CLEO-CD</acronym>
  <official_title>COVID-19 Related Lockdown Effects On Chronic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The containment associated with the VIDOC-19 pandemic creates an unprecedented societal&#xD;
      situation of physical and social isolation. Our hypothesis is that in patients with chronic&#xD;
      diseases, confinement leads to changes in health behaviours, adherence to pharmacological&#xD;
      treatment, lifestyle rules and increased psychosocial stress with an increased risk of&#xD;
      deterioration in their health status in the short, medium and long term.&#xD;
&#xD;
      Some messages about the additional risk/danger associated with taking certain drugs in the&#xD;
      event of COVID disease have been widely disseminated in the media since March 17, 2020, the&#xD;
      date on which containment began in France. This is the case, for example, for&#xD;
      corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme&#xD;
      inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major&#xD;
      classes of drugs are widely prescribed in patients with chronic diseases, diseases&#xD;
      specifically selected in our study (corticosteroids: haematological malignancies, multiple&#xD;
      sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery&#xD;
      disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a&#xD;
      secondary prophylaxis after a myocardial infarction can be stopped by some patients who&#xD;
      consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this&#xD;
      antiplatelet agent, which must be taken for life after an infarction, exposes the patient to&#xD;
      a major risk of a new cardiovascular event.&#xD;
&#xD;
      The current difficulty of access to care due to travel restrictions (a theoretical limit in&#xD;
      the context of French confinement but a priori very real), the impossibility of consulting&#xD;
      overloaded doctors, or the cancellation of medical appointments, medical and surgical&#xD;
      procedures due to the reorganization of our hospital and private health system to better&#xD;
      manage COVID-19 patients also increases the risk of worsening the health status of chronic&#xD;
      patients who by definition require regular medical monitoring.&#xD;
&#xD;
      Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease,&#xD;
      heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic&#xD;
      respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health&#xD;
      impact of the containment related to the COVID-19 pandemic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">November 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>% adherence to each pharmacological class</measure>
    <time_frame>during the period from 20 April 2020 to 7 May 2020</time_frame>
    <description>increase in dose, decrease in dose, discontinuation or no change for each drug class)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of occurrence of medical events at 1 year</measure>
    <time_frame>throughout the study for 12 months</time_frame>
    <description>(mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expressed in %: Non-pharmacological treatment/lifestyle:</measure>
    <time_frame>during the period from 20 April 2020 to 7 May 2020</time_frame>
    <description>Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication</measure>
    <time_frame>during the period from 20 April 2020 to 7 May 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)</measure>
    <time_frame>during the period from 20 April 2020 to 7 May 2020</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">1200</enrollment>
  <condition>Chronic Coronary Syndrome</condition>
  <condition>Heart Failure</condition>
  <condition>AMD and Macular Edema</condition>
  <condition>Chronic Respiratory Failure</condition>
  <condition>Hemophilia</condition>
  <condition>Malignant Hemopathy</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Horton's Disease</condition>
  <arm_group>
    <arm_group_label>Register of haematological malignancies</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic Pulmonary Fibrosis and PAH Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Giant Cell Arteritis Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>AMD and Macular Edema Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Myocardial Infarction Observatory RICO</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Failure Cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemophilia Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>life questionnaires</intervention_name>
    <description>Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)</description>
    <arm_group_label>AMD and Macular Edema Cohort</arm_group_label>
    <arm_group_label>Giant Cell Arteritis Cohort</arm_group_label>
    <arm_group_label>Heart Failure Cohort</arm_group_label>
    <arm_group_label>Hemophilia Cohort</arm_group_label>
    <arm_group_label>Idiopathic Pulmonary Fibrosis and PAH Cohort</arm_group_label>
    <arm_group_label>Multiple Sclerosis Cohort</arm_group_label>
    <arm_group_label>Myocardial Infarction Observatory RICO</arm_group_label>
    <arm_group_label>Register of haematological malignancies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease</description>
    <arm_group_label>AMD and Macular Edema Cohort</arm_group_label>
    <arm_group_label>Giant Cell Arteritis Cohort</arm_group_label>
    <arm_group_label>Heart Failure Cohort</arm_group_label>
    <arm_group_label>Hemophilia Cohort</arm_group_label>
    <arm_group_label>Idiopathic Pulmonary Fibrosis and PAH Cohort</arm_group_label>
    <arm_group_label>Multiple Sclerosis Cohort</arm_group_label>
    <arm_group_label>Myocardial Infarction Observatory RICO</arm_group_label>
    <arm_group_label>Register of haematological malignancies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients from existing registries or cohorts&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with one of the following chronic diseases: chronic coronary syndrome, heart&#xD;
             failure, multiple sclerosis, Horton's disease, AMD, malignant haemopathy, chronic&#xD;
             respiratory failure (idiopathic fibrosis, PAH, haemophilia) and already registered in&#xD;
             one of the 8 Burgundian registries/cohorts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  deceased patient, patient cannot be reached after &gt;3 telephone calls, patient or&#xD;
             caregiver does not speak French to carry out telephone interviews&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

